EUVIMEDEUVIMED entdecken
Übersichtsarbeit

T cell engagers emerge as a compelling therapeutic modality

P A Baeuerle iD, K Sauer iD, R Grieshaber-Bouyer iD, J S Michaelson iD

Journal of Experimental Medicine · 2026

DOI: 10.1084/jem.20251652 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Experimental Medicine, 2026. Verfasst von P A Baeuerle und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cullinan Therapeutics , Cambridge, MA, USA. Hauptthemen laut MEDLINE: Neoplasms, T-Lymphocytes, T-Lymphocytes, Cytotoxic. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 144 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cell engagers (TCEs) are antibody-based constructs designed to transiently reprogram cytotoxic T lymphocytes for target cell elimination by simultaneously binding the T cell receptor and a specific surface antigen on the target cell. Over the past 12 years, 10 TCEs were approved by the US Food and Drug Administration, and an additional two by the European Medicines Agency. Nine TCEs treat hematologic malignancies, and three target solid tumors. Over 150 TCEs are being investigated in clinical trials, recently also in autoimmune diseases. Here, we discuss the learnings from the 12 approved TCEs. A surprising variety of molecular designs and biochemical characteristics appear suitable for approval. On the clinical side, we review targets, indications, dosing, schedules, side effects, mitigation strategies for adverse events, and efficacy. High flexibility in design and choice of target, scalability, high response rates as a monotherapy in hematologic malignancies, and emerging efficacy against solid tumors and in autoimmune diseases make TCEs an attractive therapeutic modality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsT-LymphocytesT-Lymphocytes, CytotoxicHumansReceptors, Antigen, T-CellAutoimmune DiseasesAnimalsHematologic NeoplasmsImmunotherapy

Substanzen

Receptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Cullinan Therapeutics , Cambridge, MA, USA.
  • Institute for Immunology, Faculty of Medicine, Biomedical Center, Ludwig-Maximilians-Universität München , Martinsried-Planegg, Germany.
  • Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
  • Department of Internal Medicine 3, Rheumatology and Immunology, Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

ORCID-Profile: P A Baeuerle, K Sauer, R Grieshaber-Bouyer, J S Michaelson

Zitieren

APA

Baeuerle, P. A., Sauer, K., Grieshaber-Bouyer, R., & Michaelson, J. S. (2026). T cell engagers emerge as a compelling therapeutic modality. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20251652

Vancouver

Baeuerle PA, Sauer K, Grieshaber-Bouyer R, Michaelson JS. T cell engagers emerge as a compelling therapeutic modality. Journal of Experimental Medicine. 2026. doi:10.1084/jem.20251652

BibTeX
@article{Baeuerle2026,
  author = {Baeuerle, P A and Sauer, K and Grieshaber-Bouyer, R and Michaelson, J S},
  title = {T cell engagers emerge as a compelling therapeutic modality},
  journal = {Journal of Experimental Medicine},
  year = {2026},
  doi = {10.1084/jem.20251652}
}
Kostenlos starten →